

DOCKET NO.: L0624.70002US00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Ya Fang Liu

Serial No.:

10/042,614

Confirmation No.:

6176

Filed:

January 9, 2002

For:

JNK INHIBITORS FOR TREATMENT OF

NEUROLOGICAL DISORDERS

Examiner:

Susan Marie Hanley

Art Unit:

1651

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 14th day of October, 2005.

Mail Stop AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed more than three months after the filing date of this application and after the mailing date of the first Office Action, but before the mailing date of either a final action under 37 C.F.R. §1.113 or a Notice of Allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in this application.

The fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) is enclosed.

10/20/2005 FMETEKI1 00000053 10042614

02 FC:1806

180.00 OP

Serial No.: 10/042,614 - 2 - Art Unit: 1651

Conf. No.: 6176

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

- 1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
- 2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
- 3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

Mary Market Company of the Company o

Art Unit: 1651 Serial No.: 10/042,614 - 3 -

Conf. No.: 6176

An early and favorable action is hereby requested.

Respectfully submitted, Ya Fang Liu, Applicant

John R. Van Amsterdam, Reg. No. 40,212 Wolf, Greenfield & Sacks, P.C.

600 Atlantic Avenue

भी देनीया । भी ५१७ वर्ग

Boston, Massachusetts 02210-2206

Telephone: (617) 646-8000

Docket No.: L0624.70002US00

Dated: October 14, 2005

xNDDx

	OCT 19 2005	7			
FORM PTO (Modified) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/042,614	DOCKET NO.: L0624.70002US00
				FILING DATE: January 9, 2002	CONFIRMATION NO.: 6176
				APPLICANT: Ya Fang Liu	
				GROUP ART UNIT: 1651	EXAMINER: Susan Marie Hanley
Sheet	l	of	1		

U.S. PATENT DOCUMENTS

Examiner's Initials	Cite No.	U.S. Patent Docum	ent	Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY	
		Number	Kind Code			
		,				

FOREIGN PATENT DOCUMENTS

- Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited	Date of Publication of	Translation
		Office/ Country	Number	r Kind Code	Document (not necessary)	Cited Document MM-DD-YYYY	(Y/N)
				<u>:</u>			
				:4.[(N 25 1 1 1		
•				V	and additional to the second of the second o		

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Transl (Y/	
	C1	MARONEY, et al., "CEP-1347 (KT7515), a Semisynthetic Inhibitor of the Mixed Lineage Kinase Family," The Journal of Biological Chemistry, Vol. 276, No. 27, Issue of July 6, pp. 25302-25308		

EXAMINER:	DATE CONSIDERED:

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - The Office has waived the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications.]

OIPE >